The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia

Cover
Title
Copyright
Contents
Acronyms/Abbreviations
Introduction
	Rationale
	Scope of Document
	Overview of the Development Process
	Rating the Strengths of Guideline Statements and Supporting Research Evidence
	Proper Use of Guidelines
Guideline Statement Summary
Guideline Statements and Implementation
	Assessment and Determination of Treatment Plan
		Statement 1: Assessment of Possible Schizophrenia
			Implementation
			Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement
			Review of Available Guidelines From Other Organizations
			Quality Measurement Considerations
		Statement 2: Use of Quantitative Measures
			Implementation
			Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement
			Review of Available Guidelines From Other Organizations
			Quality Measurement Considerations
		Statement 3: Evidence-Based Treatment Planning
			Implementation
			Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement
			Review of Available Guidelines From Other Organizations
			Quality Measurement Considerations
	Pharmacotherapy
		Statement 4: Antipsychotic Medications
			Implementation
			Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement
			Review of Available Guidelines From Other Organizations
			Quality Measurement Considerations
		Statement 5: Continuing Medications
			Implementation
			Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement
			Review of Available Guidelines From Other Organizations
			Quality Measurement Considerations
		Statement 6: Continuing the Same Medications
			Implementation
			Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement
			Review of Available Guidelines From Other Organizations
			Quality Measurement Considerations
		Statement 7: Clozapine in Treatment-Resistant Schizophrenia
			Implementation
			Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement
			Review of Available Guidelines From Other Organizations
			Quality Measurement Considerations
		Statement 8: Clozapine in Suicide Risk
			Implementation
			Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement
			Review of Available Guidelines From Other Organizations
			Quality Measurement Considerations
		Statement 9: Clozapine in Aggressive Behavior
			Implementation
			Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement
			Review of Available Guidelines From Other Organizations
			Quality Measurement Considerations
		Statement 10: Long-Acting Injectable Antipsychotic Medications
			Implementation
			Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement
			Review of Available Guidelines From Other Organizations
			Quality Measurement Considerations
		Statement 11: Anticholinergic Medications for Acute Dystonia
			Implementation
			Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement
			Review of Available Guidelines From Other Organizations
			Quality Measurement Considerations
		Statement 12: Treatments for Parkinsonism
			Implementation
			Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement
			Review of Available Guidelines From Other Organizations
			Quality Measurement Considerations
		Statement 13: Treatments for Akathisia
			Implementation
			Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement
			Review of Available Guidelines From Other Organizations
			Quality Measurement Considerations
		Statement 14: VMAT2 Medications for Tardive Dyskinesia
			Implementation
			Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement
			Review of Available Guidelines From Other Organizations
			Quality Measurement Considerations
	Psychosocial Interventions
		Statement 15: Coordinated Specialty Care Programs
			Implementation
			Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement
			Review of Available Guidelines From Other Organizations
			Quality Measurement Considerations
		Statement 16: Cognitive-Behavioral Therapy
			Implementation
			Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement
			Review of Available Guidelines From Other Organizations
			Quality Measurement Considerations
		Statement 17: Psychoeducation
			Implementation
			Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement
			Review of Available Guidelines From Other Organizations
			Quality Measurement Considerations
		Statement 18: Supported Employment Services
			Implementation
			Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement
			Review of Available Guidelines From Other Organizations
			Quality Measurement Considerations
		Statement 19: Assertive Community Treatment
			Implementation
			Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement
			Review of Available Guidelines From Other Organizations
			Quality Measurement Considerations
		Statement 20: Family Interventions
			Implementation
			Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement
			Review of Available Guidelines From Other Organizations
			Quality Measurement Considerations
		Statement 21: Self-Management Skills and Recovery-Focused Interventions
			Implementation
			Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement
			Review of Available Guidelines From Other Organizations
			Quality Measurement Considerations
		Statement 22: Cognitive Remediation
			Implementation
			Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement
			Review of Available Guidelines From Other Organizations
			Quality Measurement Considerations
		Statement 23: Social Skills Training
			Implementation
			Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement
			Review of Available Guidelines From Other Organizations
			Quality Measurement Considerations
		Statement 24: Supportive Psychotherapy
			Implementation
			Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement
			Review of Available Guidelines From Other Organizations
			Quality Measurement Considerations
Areas for Further Research in Individuals With Schizophrenia
Guideline Development Process
	Management of Potential Conflicts of Interest
	Guideline Writing Group Composition
	Systematic Review Methodology
	Rating the Strength of Supporting Research Evidence
	Rating the Strength of Guideline Statements
	Use of Guidelines to Enhance Quality of Care
	External Review
	Funding and Approval
Glossary of Terms
References
Disclosures
Individuals and Organizations That Submitted Comments
Appendix A. Clinical Questions
Appendix B. Search Strategies, Study Selection, and Search Results
	AHRQ Review
	Treatment of Neurological Side Effects of Antipsychotic Medications
Appendix C. Review of Research Evidence Supporting Guideline Statements
	Assessment and Determination of Treatment Plan
		Statement 1: Assessment of Possible Schizophrenia
		Statement 2: Use of Quantitative Measures
		Statement 3: Evidence-Based Treatment Planning
	Pharmacotherapy
		Statement 4: Antipsychotic Medications
		Statement 5: Continuing Medications
		Statement 6: Continuing the Same Medications
		Statement 7: Clozapine in Treatment-Resistant Schizophrenia
		Statement 8: Clozapine in Suicide Risk
		Statement 9: Clozapine in Aggressive Behavior
		Statement 10: Long-Acting Injectable Antipsychotic Medications
		Statement 11: Anticholinergic Medications for Acute Dystonia
		Statement 12: Treatments for Parkinsonism
		Statement 13: Treatments for Akathisia
		Statement 14: VMAT2 Medications for Tardive Dyskinesia
	Psychosocial Interventions
		Statement 15: Coordinated Specialty Care Programs
		Statement 16: Cognitive-Behavioral Therapy
		Statement 17: Psychoeducation
		Statement 18: Supported Employment Services
		Statement 19: Assertive Community Treatment
		Statement 20: Family Interventions
		Statement 21: Self-Management Skills and Recovery-Focused Interventions
		Statement 22: Cognitive Remediation
		Statement 23: Social Skills Training
		Statement 24: Supportive Psychotherapy
Appendix D. Strength of Evidence
	Table D–1. Pharmacological treatment
	Table D–2. Assertive community treatment (ACT)
	Table D–3. Cognitive-behavioral therapy (CBT)
	Table D–4. Cognitive remediation
	Table D–5. Family interventions
	Table D–6. Intensive case management
	Table D–7. Illness management and recovery
	Table D–8. Psychoeducation
	Table D–9. Social skills training
	Table D–10. Supported employment
	Table D–11. Supportive therapy
	Table D–12. Early interventions for patients with first-episode psychosis
	Table D–13. Co-occurring substance use and schizophrenia
Back Cover